Get started

Financials · LUCD

Lucid Diagnostics Inc. (LUCD) financials

For the twelve months ended Jun 30, 2026, Lucid Diagnostics Inc. reported $5.45M of revenue and -$52.26M of net income.

Revenue, TTM
$5.45M
Revenue growth, YoY
+24.9%
Net income, TTM
-$52.26M
Net margin
-959.8%
Cash
$33.40M
P/S
15.60
Market cap
$84.9M
Annual revenue$4.71M
FY2021FY2025
Annual net income-$58.01M
FY2020FY2025
Annual free cash flow-$46.68M
FY2021FY2025

LUCD revenue and earnings growth

LUCD revenueQ2 2026$1.47M

Quarter YoY
+26.7%
QoQ
+17.4%
FY YoY
+8.3%

LUCD revenue was $1.47M in fiscal Q2 2026 (ended Jun 30, 2026), up 26.7% from a year earlier and up 17.4% from the prior quarter. For the full fiscal 2025 it was $4.71M, up 8.3% from fiscal 2024. It rose in 3 of the last 4 fiscal years. Fiscal 2025 is the highest of the 5 fiscal years on file.

LUCD net incomeQ2 2026-$11.69M

LUCD net income was -$11.69M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.44M a year earlier. For the full fiscal 2025 it was -$58.01M, compared with -$45.53M in fiscal 2024.

LUCD EPSQ3 2025-$0.10

LUCD diluted EPS was -$0.10 in fiscal Q3 2025 (ended Sep 30, 2025). For the full fiscal 2024 it was -$1.05, compared with -$1.26 in fiscal 2023.

LUCD free cash flowQ2 2026-$11.32M

LUCD free cash flow was -$11.32M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$10.57M a year earlier. For the full fiscal 2025 it was -$46.68M, compared with -$44.44M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$4.71M$4.35M$2.43M$377.0K$500.0K-
Cost of revenue$6.67M$7.10M-$100.00M$585.0K-
Gross profit-$1.96M-$2.75M-$377.0K$500.0K-
Research and development$5.68M$5.99M$7.25M$11.26M$9.30M$5.44M
Selling, general and admin$23.87M$20.16M$19.25M$23.97M$21.0K$7.0K
Operating income-$49.64M-$46.05M-$48.48M-$56.25M-$27.42M-$8.28M
Interest expense$22.0K$26.0K$416.0K$8.0K--
Pre-tax income-$58.01M-$45.53M-$52.67M-$56.17M-$28.08M-$8.28M
Income tax$0$0----
Net income-$58.01M-$45.53M-$52.67M-$56.17M-$28.08M-$8.28M
EPS, basic-$0.69-$1.05-$1.26-$1.55-$1.51-$0.59
EPS, diluted--$1.05-$1.26-$1.55-$1.51-$0.59
Diluted shares-50.5M41.8M36.2M18.6M14.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$34.70M$22.36M$18.90M$22.47M$53.66M$111.0K
Receivables$643.0K$45.0K$45.0K$17.0K$200.0K-
Inventory$353.0K$341.0K$278.0K$111.0K--
Current assets$37.47M$25.15M$22.07M$24.36M$57.30M$1.44M
Total assets$40.45M$30.71M$27.27M$32.51M$59.00M$2.19M
Current liabilities$28.58M$23.52M$29.38M$8.43M$4.26M-
Total debt-----$13.26M
Total liabilities$29.51M$25.32M$29.58M$9.46M$4.26M$15.71M
Shareholders' equity$10.94M$5.39M-$2.31M$23.05M$54.74M-$13.52M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$46.48M-$44.14M-$32.82M-$29.68M-$17.67M-$5.63M
Capital expenditures$197.0K$296.0K-$3.20M$862.0K-
Free cash flow-$46.68M-$44.44M--$32.88M-$18.53M-
Investing cash flow-$197.0K-$646.0K-$221.0K-$4.11M-$862.0K-
Financing cash flow$59.03M$48.25M$29.46M$2.61M$72.08M$5.58M
Stock-based compensation-$4.18M$5.76M$13.86M$9.13M$65.0K
Depreciation and amortization$872.0K$1.17M$2.50M$1.94M$4.0K-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue growth, YoY8.3%79.0%544.0%-24.6%--
Gross margin-41.7%-63.3%-100.0%100.0%-
Operating margin-1054.8%-1059.6%-1996.8%-14920.7%-5483.8%-
Net margin-1232.7%-1047.6%-2169.1%-14899.5%-5615.6%-
Free cash flow margin-992.0%-1022.5%--8722.8%-3706.0%-
Return on equity-530.4%-844.5%--243.7%-51.3%-
Return on assets-143.4%-148.2%-193.1%-172.8%-47.6%-377.2%
Current ratio1.311.070.752.8913.45-

Source: XBRL data Lucid Diagnostics Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

LUCD peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
LUCD$5.45M+24.9%-$52.26M-959.8%$84.9M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

LUCD FAQ

6 questions
  • What is LUCD revenue?
    Lucid Diagnostics Inc. (LUCD) reported $5.45M of revenue for the twelve months ended Jun 30, 2026. That is up 24.9% from the year before. Revenue for fiscal 2025 was $4.71M.
  • Is LUCD profitable?
    No. Lucid Diagnostics Inc. reported a net loss of $52.26M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does LUCD have?
    Lucid Diagnostics Inc. reported $33.40M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is LUCD revenue growing?
    Lucid Diagnostics Inc.'s revenue changed +8.3% in fiscal 2025, to $4.71M.
  • When did LUCD last report financial results?
    The latest statements here come from Lucid Diagnostics Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.
  • Where does this LUCD financial data come from?
    Quantisnow builds these statements from the structured XBRL data Lucid Diagnostics Inc. files with the SEC. It is provided for information only and is not investment advice.